Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Contrafect (NQ: CFRX )

5.410 USD -0.010 (-0.18%)
Official Closing Price Updated: 7:57 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Contrafect

< Previous 1 2 3 4 5 Next >
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
From GlobeNewswire News Releases
ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference
From GlobeNewswire News Releases
ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis 
From GlobeNewswire News Releases
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
From GlobeNewswire News Releases
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
From GlobeNewswire News Releases
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
From GlobeNewswire News Releases
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
From GlobeNewswire News Releases
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
From GlobeNewswire News Releases
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
From GlobeNewswire News Releases
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
Abstracts highlight the advancement of three new antibacterial modalities: novel native lysins, engineered lysins and amurin peptides 
From GlobeNewswire News Releases
ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference
From GlobeNewswire News Releases
ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
From GlobeNewswire News Releases
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
From GlobeNewswire News Releases
ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development
From GlobeNewswire News Releases
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditi
From GlobeNewswire News Releases
ContraFect Announces One-for-Ten Reverse Stock Split
From GlobeNewswire News Releases
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
From GlobeNewswire News Releases
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
From GlobeNewswire News Releases
ContraFect to Present at 2020 ASM Biothreats
From GlobeNewswire News Releases
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
From GlobeNewswire News Releases
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
From GlobeNewswire News Releases
ContraFect to Present at Biotech Showcase 2020
From GlobeNewswire News Releases
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia 
From GlobeNewswire News Releases
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa 
From GlobeNewswire News Releases
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock
From GlobeNewswire News Releases
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
From GlobeNewswire News Releases
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.